LCM
MRNA icon

Laurion Capital Management’s Moderna MRNA Stock Holding History

Laurion Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,840
Closed -$456K – 484
2024
Q2 		$456K Buy
+3,840
New +$486K 0.01% 369
2024
Q1 		– Sell
-32,800
Closed -$3.26M – 589
2023
Q4 		$3.26M Buy
+32,800
New +$2.76M 0.03% 269
2022
Q3 		– Sell
-2,871
Closed -$410K – 567
2022
Q2 		$410K Buy
+2,871
New +$410K 0.01% 350
2022
Q1 		– Sell
-1,048
Closed -$266K – 651
2021
Q4 		$266K Buy
+1,048
New +$306K ﹤0.01% 472
2020
Q2 		– Sell
-304,900
Closed -$9.13M – 1066
2020
Q1 		$9.13M Buy
+304,900
New +$7.01M 0.1% 186
2019
Q4 		– Sell
-32,819
Closed -$522K – 1102
2019
Q3 		$522K Sell
32,819
-99,600
-75% -$1.47M ﹤0.01% 763
2019
Q2 		$1.94M Sell
132,419
-117,581
-47% -$2.53M 0.02% 389
2019
Q1 		$5.09M Hold
250,000
– – 0.07% 210
2018
Q4 		$3.82M Buy
+250,000
New +$4.11M 0.07% 341

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Laurion Capital Management's MRNA Position: Q3 2024 in Review

Laurion Capital Management sold out of Moderna (MRNA) in Q3 2024, closing a stake of 3,840 shares — an estimated $456K sold.

Laurion Capital Management first reported a position in MRNA in Q4 2018 and held it in 9 quarters. The position peaked at $9.13M in Q1 2020. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Laurion Capital Management reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Laurion Capital Management sold 3,840 Moderna shares in Q3 2024, an estimated $456K.
  • Laurion Capital Management first reported a position in Moderna in Q4 2018 and held it in 9 quarters.
  • Laurion Capital Management's Moderna position peaked at $9.13M in Q1 2020.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Laurion Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.